Skip to main content
Erschienen in: International Cancer Conference Journal 3/2016

05.02.2016 | Case report

Rechallenge with 5-fluorouracil in a patient who developed encephalopathy caused by 5-fluorouracil for colon cancer

verfasst von: Takeshi Yamada, Hayato Kan, Satoshi Matsumoto, Michihiro Koizumi, Seiichi Shinji, Akihisa Matsuda, Aya Yamagishi, Yasuyuki Yokoyama, Goro Takahashi, Takuma Iwai, Eiji Uchida

Erschienen in: International Cancer Conference Journal | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

We report a case involving a patient with colon cancer who underwent 5-fluorouracil (5-FU) rechallenge and maintained an oncological effect for a long period after encephalopathy caused by 5-FU. Our patient was a 61-year-old man who was diagnosed with adenocarcinoma of the ascending colon with direct liver invasion. He underwent right hemicolectomy with partial liver resection followed by adjuvant chemotherapy with modified FOLFOX6 (mFOLFOX6). Ten months after completion of mFOLFOX6, his carcinoembryonic antigen concentration increased, and ascites was revealed by computed tomography 2 months later. We started FOLFIRI, and he was taken to our hospital by ambulance because of loss of consciousness 10 days after the start of the third cycle of FOLFIRI. Laboratory investigations showed hyperammonemia and elevations of his serum creatinine and blood urea nitrogen concentrations. Brain computed tomography demonstrated no abnormalities. Transfusion of 1500 ml of crystalloid fluid resulted in gradual recovery over the next 12 h. His ammonia concentration decreased to a normal level. Twelve days after onset of the encephalopathy, we restarted FOLFIRI, but the dose of continuous 5-FU was decreased by 20 %. The patient’s carcinoembryonic antigen concentration considerably decreased from 376.5 to 19.9 ng/ml, and his ascites disappeared. Nineteen months after the resumption of FOLFIRI, he underwent 34 courses of FOLFIRI and maintained stable disease. The encephalopathy did not recur.
Literatur
1.
Zurück zum Zitat Advani PP, Fakih MG (2011) 5-FU-induced hyperammonemic encephalopathy in a case of metastatic rectal adenocarcinoid successfully rechallenged with the fluoropyrimidine analog, capecitabine. Anticancer Res 31:335–338PubMed Advani PP, Fakih MG (2011) 5-FU-induced hyperammonemic encephalopathy in a case of metastatic rectal adenocarcinoid successfully rechallenged with the fluoropyrimidine analog, capecitabine. Anticancer Res 31:335–338PubMed
2.
Zurück zum Zitat Liaw CC, Wang HM, Wang CH et al (1999) Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. Anticancer Drugs 10:275–281CrossRefPubMed Liaw CC, Wang HM, Wang CH et al (1999) Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. Anticancer Drugs 10:275–281CrossRefPubMed
3.
Zurück zum Zitat Yeh KH, Cheng AL (1997) High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. Br J Cancer 75:464–465CrossRefPubMedPubMedCentral Yeh KH, Cheng AL (1997) High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. Br J Cancer 75:464–465CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Sharief U, Perry DJ (2009) Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin. Clin Colorectal Cancer 8:163–165CrossRefPubMed Sharief U, Perry DJ (2009) Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin. Clin Colorectal Cancer 8:163–165CrossRefPubMed
5.
Zurück zum Zitat Kim YA, Chung HC, Choi HJ et al (2006) Intermediate dose 5-fluorouracil-induced encephalopathy. Jpn J Clin Oncol 36:55–59CrossRefPubMed Kim YA, Chung HC, Choi HJ et al (2006) Intermediate dose 5-fluorouracil-induced encephalopathy. Jpn J Clin Oncol 36:55–59CrossRefPubMed
6.
Zurück zum Zitat Skelton MR, Goldberg RM, O’Neil BH (2007) A case of oxaliplatin-related posterior reversible encephalopathy syndrome. Clin Colorectal Cancer 6:386–388CrossRefPubMed Skelton MR, Goldberg RM, O’Neil BH (2007) A case of oxaliplatin-related posterior reversible encephalopathy syndrome. Clin Colorectal Cancer 6:386–388CrossRefPubMed
7.
Zurück zum Zitat Moore DH, Fowler WC Jr, Crumpler LS (1990) 5-Fluorouracil neurotoxicity. Gynecol Oncol 36:152–154CrossRefPubMed Moore DH, Fowler WC Jr, Crumpler LS (1990) 5-Fluorouracil neurotoxicity. Gynecol Oncol 36:152–154CrossRefPubMed
8.
9.
Zurück zum Zitat Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237CrossRefPubMed Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237CrossRefPubMed
10.
Zurück zum Zitat Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914CrossRefPubMed Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914CrossRefPubMed
11.
Zurück zum Zitat Thomas SA, Tomeh N, Theard S (2015) Fluorouracil-induced hyperammonemia in a patient with colorectal cancer. Anticancer Res 35:6761–6763PubMed Thomas SA, Tomeh N, Theard S (2015) Fluorouracil-induced hyperammonemia in a patient with colorectal cancer. Anticancer Res 35:6761–6763PubMed
Metadaten
Titel
Rechallenge with 5-fluorouracil in a patient who developed encephalopathy caused by 5-fluorouracil for colon cancer
verfasst von
Takeshi Yamada
Hayato Kan
Satoshi Matsumoto
Michihiro Koizumi
Seiichi Shinji
Akihisa Matsuda
Aya Yamagishi
Yasuyuki Yokoyama
Goro Takahashi
Takuma Iwai
Eiji Uchida
Publikationsdatum
05.02.2016
Verlag
Springer Japan
Erschienen in
International Cancer Conference Journal / Ausgabe 3/2016
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-016-0243-0

Weitere Artikel der Ausgabe 3/2016

International Cancer Conference Journal 3/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.